ICN Pharmaceuticals Gets FDA Approval

Drug maker ICN Pharmaceuticals Inc. said Tuesday that the U.S. Food and Drug Administration has approved the company’s antifungal medicine Nystatin.

Nystatin is a fungal antibiotic that is used as the active ingredient in a number of prescription anti-fungal medicines. It can be delivered orally, by suppository, or in cream or powder form.

FDA approval brings the latest ICN medicine, made in the Czech Republic, into a competitive U.S. market in which a number of other companies already are selling their own brands of antifungals.

The Costa Mesa company said in a press release that it expects to make Nystatin available to U.S. wholesale suppliers by September.